Communiqués Heidelberg Pharma AG

Actions

HPHA

DE000A11QVV0

Recherche biotechnologique et médicale

PEA/PME

Marché Fermé - Xetra Autres places de cotation 17:36:26 17/06/2025			Après clôture 21:58:00
4,280 ^EUR	-0,70 %		4,245	-0,82 %

18:35	Heidelberg Pharma AG - Special Call
27/05	Heidelberg Pharma annonce l'administration de la première dose à un patient dans le cadre de l'étude de phase I sur le candidat ADC à base d'amanitine HDP-102 pour le lymphome non hodgkinien	CI

Communiqués

Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th	06/06	AQ
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma	27/05	EQ
Heidelberg Pharma : Bio Equity Europe 2025	20/05	PU
Heidelberg Pharma : Frühjahrskonferenz 2025 - Equity Forum	19/05	PU
PR: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board	15/05	PU
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board	15/05	EQ
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025	14/05	EQ
PR: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025	24/04	PU
Heidelberg Pharma : Interim statement on the first three months of 2025	24/04	PU
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025	24/04	EQ
Heidelberg Pharma : Remuneration Report 2024	04/04	PU
Heidelberg Pharma : Remuneration report for the 2023/2024 financial year including audit opinion (Remuneration Report Heidelberg Pharma AG 2024 eng)	04/04	PU
Heidelberg Pharma : CVs of the proposed Supervisory Board candidates (202505 CVs AR 2025 engl final)	04/04	PU
Heidelberg Pharma : Dietmar Hopp	03/04	PU
Heidelberg Pharma : Daniel Hopp	03/04	PU
Heidelberg Pharma : Christof Hettich	03/04	PU
Heidelberg Pharma : Friedrich von Bohlen	03/04	PU
Heidelberg Pharma : Information pursuant to § 125 AktG and Table 3 Blocks A to F Implementing Regulation EU 2018/1212) (HDP Informationen nach 125 AktG englisch und Tabelle 3 Blocke A bis F Durchfuhrungsverordnung EU 2018 1212 MOR copy 1)	02/04	PU
Heidelberg Pharma : Report of the Management Board on agenda item 9 (HDP Written management report on agenda item 9)	02/04	PU
Heidelberg Pharma : Explanations on the resolutionless agenda item 1 (HDP Explanations with regard to item 1 of the agenda copy 1)	02/04	PU
Heidelberg Pharma : Explanation of shareholders' rights (HDP explanations of the rights of shareholders copy 1)	02/04	PU
Heidelberg Pharma : Proxy to a third person (HDP Proxy to a person of your choice copy 1)	02/04	PU
Heidelberg Pharma : Revocation of proxy (HDP Revocation copy 1)	02/04	PU
Heidelberg Pharma : Information on data protection (HDP Data protection information for shareholders copy 1)	02/04	PU
Heidelberg Pharma : Agenda and convening of the general meeting (HDP Agenda AGM 2025)	02/04	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Heidelberg Pharma AG

Actions

HPHA

DE000A11QVV0

Recherche biotechnologique et médicale

PEA/PME

Communiqués

Filtres